Ublituximab: A new FDA-approved anti-CD20 mAb for relapsing forms of multiple sclerosis.

Abstract

Ublituximab, an intravenous glycoengineered chimeric anti-CD20 IgG1 monoclonal antibody (mAb), is a new FDA-approved treatment for relapsing forms of Multiple Sclerosis (MS). Reassembling the other three anti-CD20 mAbs already in use for MS (rituximab, ocrelizumab and ofatumumab), ublituximab leads to depletion of B cells but spars long-lived plasma cells. Here, we discuss the main findings obtained during the phase 3 clinical trials (ULTIMATE I and II) for ublituximab versus teriflunomide. The current emergence and approval of new anti-CD20 mAbs with different dose regimens, routes of application, glycoengineering and mechanisms of action may contribute to different clinical outcomes.

• Authors: Vinícius Oliveira Boldrini, Simone Mader, Tania Kümpfel, Edgar Meinl
• Journal: Multiple sclerosis and related disorders (Mult Scler Relat Disord) Vol. 75 Pg. 104733 (Jul 2023) ISSN: 2211-0356 [Electronic] Netherlands
• PMID: 37156035 (Publication Type: Letter)
• Copyright: Copyright © 2023. Published by Elsevier B.V.

Chemical References

• ublituximab
• Antigens, CD20
• Antibodies, Monoclonal
• Rituximab
• Antineoplastic Agents

Topics

• Humans
• Multiple Sclerosis (drug therapy)
• Antigens, CD20
• Antibodies, Monoclonal (therapeutic use)
• Rituximab (therapeutic use)
• Antineoplastic Agents (therapeutic use)